Last reviewed: May 17, 2026
Last updated: May 17, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Reflexmd and Henry Meds both deliver telehealth GLP-1 services, but operational and clinical models differ meaningfully. Understanding these distinctions—pharmacy sourcing, provider oversight depth, and cost structure—helps patients make informed decisions aligned with evidence-based care principles.
Choosing between telemedicine GLP-1 providers requires evaluating more than price alone. Genetic predispositions in peptide pathways, baseline metabolic markers, and provider engagement depth all influence treatment success. PlexusDx prioritizes transparency around compounding sourcing and personalized clinical context to support your decision.
Pharmacy Sourcing and Manufacturing Standards
Both platforms source compounded GLP-1 medications, but sourcing standards vary. Reflexmd and Henry Meds partner with different compounding facilities, each operating under state pharmacy regulations. Understanding whether your provider uses 503A (traditional) versus 503B (outsourcing) facilities matters for quality assurance and oversight.
PlexusDx exclusively partners with licensed 503A compounding pharmacies, which operate under stricter state board oversight and individual patient-by-patient compounding protocols. This sourcing transparency allows patients and providers to discuss quality assurance frameworks directly, supporting informed consent.
Pricing, Subscription Models, and Cost Transparency
Reflexmd and Henry Meds structure pricing differently. Some operate on monthly subscription models with variable dosing costs; others charge per-prescription fees. Hidden costs—consultation fees, shipping, or tiered dosing—can affect total treatment expense. Comparing true all-in monthly costs is essential before enrollment.
| Pricing Element |
What to Evaluate |
| Monthly medication cost |
Base price plus any mandatory subscription tiers or bundling |
| Consultation and provider fees |
Initial assessment, follow-up visits, and adjustment consultations |
| Shipping and handling |
Flat rate vs. per-order charges; cold-chain fees if applicable |
| Dosing escalation costs |
Whether dose increases incur additional fees or remain included |
| Generic or compounded options |
Whether pricing differs for semaglutide versus tirzepatide formulations |
Provider Oversight Depth and Clinical Accountability
Provider involvement varies across platforms. Some telemedicine GLP-1 services assign a single provider for continuity; others rotate clinicians. Depth of baseline assessment—blood work, metabolic panels, cardiovascular screening—differs meaningfully. Ongoing monitoring protocols and adjustability of treatment also vary.
Deeper provider oversight typically includes baseline labs (fasting glucose, HbA1c, lipids, renal function), detailed medication history review, and structured follow-up schedules. This accountability framework reduces adverse events and supports dose optimization. Ask prospective providers about their specific baseline assessment and monitoring cadence.
Genetic and Biomarker Context for Personalized Treatment
Neither Reflexmd nor Henry Meds typically offers genetic predisposition testing as part of routine assessment. Yet emerging evidence shows that variants in GLP-1 receptor (GLP1R), glucose-dependent insulinotropic peptide receptor (GIPR), and metabolic genes (FTO, MC4R) may influence individual response patterns.
PlexusDx's Precision Peptide Genetic Test examines key variants in peptide pathways that may help contextualize why certain patients respond differently to GLP-1 or dual-peptide therapy. This information should always be interpreted with a qualified provider and does not predict exact medication response. Instead, it may help guide more informed conversations about treatment selection and monitoring expectations.
How PlexusDx Supports a More Personalized Approach
PlexusDx differentiates through transparent 503A compounding sourcing and integration of genetic predisposition data. The Precision Peptide Genetic Test examines variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—markers that may help provide context for individual peptide pathway responsiveness. This information is designed to support more personalized conversations with your provider, not replace clinical judgment.
The Precision Peptide test reveals genetic predispositions in peptide signaling pathways, which may help explain variable treatment responses observed in clinical practice. Patients with specific genetic profiles may benefit from different initial dosing strategies, compound selections (semaglutide vs. tirzepatide), or monitoring intensities. Genetic context should always be interpreted alongside lifestyle, metabolic markers, and clinical history.
If you're evaluating GLP-1 providers, consider requesting baseline genetic assessment or biomarker panels to support provider decision-making. PlexusDx offers the Precision Peptide Genetic Test as a standalone assessment ($298) or add-on to any medication program ($99), enabling more informed dialogue about personalized treatment strategies with your healthcare team.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the main difference between Reflexmd and Henry Meds for GLP-1 access?
Both offer telemedicine GLP-1 services, but differ in pharmacy partnerships, provider continuity models, baseline assessment depth, and pricing structures. Reflexmd and Henry Meds may also differ in follow-up monitoring protocols and medication sourcing standards.
How do I know if a telemedicine GLP-1 provider uses safe compounding practices?
Ask whether the provider partners exclusively with 503A state-licensed compounding pharmacies, which operate under stricter individual patient-by-patient oversight. Request information about pharmacy accreditation, quality assurance protocols, and batch testing standards before enrollment.
Does PlexusDx offer pricing comparable to Reflexmd or Henry Meds?
PlexusDx compounded semaglutide starts at $149/mo and tirzepatide at $249/mo from licensed 503A pharmacies. Oral formulations are also available. Compare these costs directly with other providers' all-in monthly fees, including consultations and shipping.
What baseline tests should a GLP-1 provider order before starting treatment?
Standard baseline assessment includes fasting glucose, HbA1c, lipid panel, renal function (creatinine, eGFR), liver enzymes, and cardiovascular risk evaluation. Some providers add additional markers like metabolic syndrome screening or thyroid function depending on individual history.
Can genetic testing help me choose between Reflexmd, Henry Meds, or another GLP-1 provider?
The PlexusDx Precision Peptide Genetic Test examines predispositions in GLP1R, GIPR, FTO, and MC4R pathways that may provide context for individual treatment response patterns. This information should be discussed with your provider to support more personalized dosing or compound selection strategies.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Weightwatchers Cost: Why Biomarkers Matter for Your Weight-Loss Strategy
PlushCare Cost Guide: Tiers, Eligibility Discounts, and What Affects